NEWS

News Articles

U.S. FDA Approves UCB’s Drug for Rare Childhood Epilepsy

April 1, 2022

Belgian biotech firm UCB SA said on Monday the U.S. Food and Drug Administration (FDA) approved its drug to treat seizures associated with Lennox-Gastaut Syndrome (LGS), a rare form of childhood epilepsy. The drug, branded as Fintepla, already has the U.S. approval to treat another form of childhood-onset epilepsy, Davet Syndrome (DS), in patients aged…

Read More

Emory researchers have identified antibodies that may be able to defend people against multiple species of the Ebola virus family.

April 1, 2022

Researchers have identified antibodies that may be able to defend people against multiple species of the Ebola virus family. The antibodies were derived from two individuals who survived Ebola virus disease and were treated at Emory University Hospital in 2014. The findings were published in Cell, following a collaboration between the lab of Rafi Ahmed, PhD,…

Read More

Mercer recognized with CUR’s Campus-Wide Award for Undergraduate Research Accomplishments

April 1, 2022

Mercer University is one of three recipients of the worldwide Council on Undergraduate Research’s (CUR) Campus-Wide Award for Undergraduate Research Accomplishments (AURA). The annual award, which recognizes institutions with exemplary programs that provide high-quality research experiences for undergraduates, will be formally presented during a virtual ceremony on April 21 as part of national Undergraduate Research Week.…

Read More

U.S. FDA Approves FINTEPLA® ▼(fenfluramine) Oral Solution for Treatment of Seizures Associated with Lennox-Gastaut Syndrome (LGS)

March 28, 2022

Approval based on data where fenfluramine demonstrated efficacy in the most difficult to treat seizure types,1,2 including drop seizures, which cause a person to suddenly lose muscle tone, become limp, and fall to the ground with a high likelihood of injury3 LGS is a severe childhood-onset developmental and epileptic encephalopathy characterized by drug-resistant seizures with high…

Read More

GeoVax Announces Issuance of Cancer Vaccine Patent

March 25, 2022

IND-Enabling Studies Underway for MVA-VLP-MUC1 Vaccine Candidate GeoVax Labs, Inc. (Nasdaq: GOVX), a biotechnology company developing human immunotherapies and vaccines against infectious diseases and cancer, today announced that the U.S. Patent and Trademark Office has issued Patent No. 11278607 to GeoVax, pursuant to the Company’s patent application No. 16/068,527 entitled “Compositions and Methods for Generating an…

Read More

Former CDC Director Dr. Robert Redfield Named PERSOWN Senior Medical Advisor

March 25, 2022

The acclaimed virologist will work with leading scientists on the development of instant electrochemical diagnostics and life-saving technologies aimed at identifying and preventing infectious diseases across the globe. PERSOWN, Inc. announced today that Dr. Robert Redfield, 18th Director of the Centers for Disease Control and Prevention (CDC), has joined their team as Senior Medical Advisor. In this…

Read More